Effect of daily IL-15 on absolute number and Ki-67 staining of CD8⁺ and CD4⁺ T_N, T_CM, and T_EM subsets. (A-B) CD8⁺ T_N, T_CM, and T_EM subsets. Samples of PBMCs from macaque 02269 (A) or macaque 05078 (B) at the indicated days before, during, and after the IL-15 treatment were stained with mAbs that bind to CD3, CD8, or CD95, and CCR7 to distinguish T_N, T_CM, and T_EM subsets, and examined by flow cytometry. The data for each T-cell subset is shown as the fold increase of the absolute numbers per microliter of blood on the indicated day relative to the absolute cell numbers per microliter of the T-cell subset enumerated on the start of the treatment. (C-D) Expression of Ki-67 by CD8⁺ T-cell subsets. The data show the fraction of cells in percentage (%) within the CD8⁺ T_N, T_CM, and T_EM subsets that express Ki-67 on the indicated days. (E-F) CD4⁺ T_N, T_CM, and T_EM subsets. Samples of PBMCs from macaque 02269 (E) or macaque 05078 (F) at the indicated days before, during, and after the IL-15 treatment were stained with mAbs that bind to CD3, CD4, or CD95, and CCR7 to distinguish T_N, T_CM, and T_EM subsets, and examined by flow cytometry. The data for each T-cell subset are shown as the fold increase of the absolute numbers per microliter of blood on the indicated day relative to the absolute cell numbers per microliter of the T-cell subset enumerated on the start of the treatment. (G-H) Expression of Ki-67 by CD4⁺ T-cell subsets. The data show the fraction of cells in percentage (%) within the CD4⁺ T_N, T_CM, and T_EM subsets that express Ki-67 on the indicated days. → indicates the duration of the IL-15 treatment.